Skip to main content

Genetic studies of neurodevelopmental disorders.

IJC2018-035346-I

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de Promoción del Talento y su Empleabilidad en I+D+i
Subprogram Subprograma Estatal de Incorporación
Call Juan de la Cierva Incorporación
Call year 2018
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACIO HOSPITAL UNIVERSITARI VALL D'HEBRON - INSTITUT DE RECERCA

Resultados relacionados

Resultados totales (Incluyendo duplicados): 5
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Shared genetic architecture between attention-deficit/hyperactivity disorder and lifespan

  • Vilar-Ribó, Laura
  • Cabana-Domínguez, Judit
  • Martorell, Lourdes
  • Ramos-Quiroga, Josep Antoni
  • Sanchez-Roige, Sandra
  • Palmer, Abraham A.
  • Vilella, Elisabet
  • Ribasés, Marta
  • Muntané, Gerard
  • Soler Artigas, María
© The Author(s) 2023. This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/., There is evidence linking ADHD to a reduced life expectancy. The mortality rate in individuals with ADHD is twice that of the general population and it is associated with several factors, such as unhealthy lifestyle behaviors, social adversity, and mental health problems that may in turn increase mortality rates. Since ADHD and lifespan are heritable, we used data from genome-wide association studies (GWAS) of ADHD and parental lifespan, as proxy of individual lifespan, to estimate their genetic correlation, identify genetic loci jointly associated with both phenotypes and assess causality. We confirmed a negative genetic correlation between ADHD and parental lifespan (rg = −0.36, P = 1.41e−16). Nineteen independent loci were jointly associated with both ADHD and parental lifespan, with most of the alleles that increased the risk for ADHD being associated with shorter lifespan. Fifteen loci were novel for ADHD and two were already present in the original GWAS on parental lifespan. Mendelian randomization analyses pointed towards a negative causal effect of ADHD liability on lifespan (P = 1.54e−06; Beta = −0.07), although these results were not confirmed by all sensitivity analyses performed, and further evidence is required. The present study provides the first evidence of a common genetic background between ADHD and lifespan, which may play a role in the reported effect of ADHD on premature mortality risk. These results are consistent with previous epidemiological data describing reduced lifespan in mental disorders and support that ADHD is an important health condition that could negatively affect future life outcomes., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-00444 and 2017SGR-1461), the Instituto de Salud Carlos III (PI18/01788, P19/01224, PI20/00041, PI21/00612, PI22/00464, FI18/00285 to LVR and CP22/00128 to MSA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD); the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014–2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN) and the ECNP Network ‘ADHD across the Lifespan’ and “la Marató de TV3” (202228-30 and 202228-31). SSR was supported by funds from the California Tobacco-Related Disease Research Program (TRDRP; Grant Number T29KT0526 and T32IR5226), and NIH/NIDA DP1DA054394. AAP was supported by NIH grant P50DA037844 and R01AA029688 and Tobacco-Related Disease Research Program Grant number: 28IR-0070., Peer reviewed
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Transcriptomic risk scores for attention deficit/hyperactivity disorder

  • Arribas, Lorena
  • Demontis, Ditte
  • Cabana-Dominguez, Judit
  • Llonga, Natalia
  • Alemany, Silvia
  • Vilar-Ribo, Laura
  • Fadeuilhe, Christian
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Soler Artigas, María
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Transcriptomic risk scores; Attention deficit and hyperactivity disorder, Puntuaciones de riesgo transcriptómico; Trastorno por déficit de atención e hiperactividad, Puntuació de risc transcriptòmic; Trastorn per dèficit d'atenció i hiperactivitat, Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus (FSE+) (P19/01224, PI20/00041, PI22/00464 and FI18/00285 to LVR, CP22/00128 to MSA and CP22/00026 to SA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD), the Network Center for Biomedical Research (CIBER) to JCD, the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’ and the “la Marató de TV3” (202228-30 and 202228-31). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003) and NIH/NIMH (1R01MH124851-01). DD was supported by the Novo Nordisk Foundation (NNF20OC0065561) and the Lundbeck Foundation (R344-2020-1060).
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Disentangling heterogeneity in substance use disorder: Insights from genome-wide polygenic scores

  • GRAU-LÓPEZ, LARA
  • Daigre, Constanza
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Heterogeneity; Substance use disorder; Genome, Heterogeneidad; Trastorno por consumo de sustancias; Genoma, Heterogeneïtat; Trastorn per consum de substàncies; Genoma, Substance use disorder (SUD) is a global health problem with a significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates. SUD often co-occurs with other psychiatric and mental health-related conditions that contribute to the heterogeneity of the disorder and predispose to adverse disease trajectories. Family and genetic studies highlight the role of genetic and environmental factors in the course of SUD, and point to a shared genetic liability between SUDs and comorbid psychopathology. In this study, we aimed to disentangle SUD heterogeneity using a deeply phenotyped SUD cohort and polygenic scores (PGSs) for psychiatric disorders and related traits. We explored associations between PGSs and various SUD-related phenotypes, as well as PGS-environment interactions using information on lifetime emotional, physical, and/or sexual abuse. Our results identify clusters of individuals who exhibit differences in their phenotypic profile and reveal different patterns of associations between SUD-related phenotypes and the genetic liability for mental health-related traits, which may help explain part of the heterogeneity observed in SUD. In our SUD sample, we found associations linking the genetic liability for attention-deficit hyperactivity disorder (ADHD) with lower educational attainment, the genetic liability for post-traumatic stress disorder (PTSD) with higher rates of unemployment, the genetic liability for educational attainment with lower rates of criminal records and unemployment, and the genetic liability for well-being with lower rates of outpatient treatments and fewer problems related to family and social relationships. We also found evidence of PGS-environment interactions showing that genetic liability for suicide attempts worsened the psychiatric status in SUD individuals with a history of emotional physical and/or sexual abuse. Collectively, these data contribute to a better understanding of the role of genetic liability for mental health-related conditions and adverse life experiences in SUD heterogeneity., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840 and 2021-SGR-01093), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to M.S.A, RYC2021-031324-I to J.C.D and PID2021-1277760B-I100 to B.C. and N.F-C.), the Ministry of Health, Social Services and Equality (PNSD-2020I042 to N.F-C.), the Network Center for Biomedical Research (CIBER) to J.C.D., the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’, “Fundació La Marató de TV3” (202228-30, 202228-31 and 202218-31) and ICREA Academia 2021.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Disentangling heterogeneity in substance use disorder: Insights from genome-wide polygenic scores

  • GRAU-LÓPEZ, LARA
  • Daigre, Constanza
  • Cabana-Dominguez, Judit
  • Soler Artigas, María
  • Alemany, Silvia
  • Llonga, Natalia
  • Vilar-Ribo, Laura
  • Arribas, Lorena
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Heterogeneity; Substance use disorder; Genome, Heterogeneidad; Trastorno por consumo de sustancias; Genoma, Heterogeneïtat; Trastorn per consum de substàncies; Genoma, Substance use disorder (SUD) is a global health problem with a significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates. SUD often co-occurs with other psychiatric and mental health-related conditions that contribute to the heterogeneity of the disorder and predispose to adverse disease trajectories. Family and genetic studies highlight the role of genetic and environmental factors in the course of SUD, and point to a shared genetic liability between SUDs and comorbid psychopathology. In this study, we aimed to disentangle SUD heterogeneity using a deeply phenotyped SUD cohort and polygenic scores (PGSs) for psychiatric disorders and related traits. We explored associations between PGSs and various SUD-related phenotypes, as well as PGS-environment interactions using information on lifetime emotional, physical, and/or sexual abuse. Our results identify clusters of individuals who exhibit differences in their phenotypic profile and reveal different patterns of associations between SUD-related phenotypes and the genetic liability for mental health-related traits, which may help explain part of the heterogeneity observed in SUD. In our SUD sample, we found associations linking the genetic liability for attention-deficit hyperactivity disorder (ADHD) with lower educational attainment, the genetic liability for post-traumatic stress disorder (PTSD) with higher rates of unemployment, the genetic liability for educational attainment with lower rates of criminal records and unemployment, and the genetic liability for well-being with lower rates of outpatient treatments and fewer problems related to family and social relationships. We also found evidence of PGS-environment interactions showing that genetic liability for suicide attempts worsened the psychiatric status in SUD individuals with a history of emotional physical and/or sexual abuse. Collectively, these data contribute to a better understanding of the role of genetic liability for mental health-related conditions and adverse life experiences in SUD heterogeneity., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840 and 2021-SGR-01093), the Instituto de Salud Carlos III (P19/01224, PI20/00041, PI22/00464, PI23/00404 and FI18/00285 to L.V.R, CP22/00128 to M.S.A and CP22/00026 to S.A), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to M.S.A, RYC2021-031324-I to J.C.D and PID2021-1277760B-I100 to B.C. and N.F-C.), the Ministry of Health, Social Services and Equality (PNSD-2020I042 to N.F-C.), the Network Center for Biomedical Research (CIBER) to J.C.D., the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’, “Fundació La Marató de TV3” (202228-30, 202228-31 and 202218-31) and ICREA Academia 2021.
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publication Artículo científico (JournalArticle)

Transcriptomic risk scores for attention deficit/hyperactivity disorder

  • Arribas, Lorena
  • Demontis, Ditte
  • Cabana-Dominguez, Judit
  • Llonga, Natalia
  • Alemany, Silvia
  • Vilar-Ribo, Laura
  • Fadeuilhe, Christian
  • Corrales, Montserrat
  • Richarte, Vanesa
  • Soler Artigas, María
  • Ribases, Marta
  • Ramos-Quiroga, Josep Antoni
Transcriptomic risk scores; Attention deficit and hyperactivity disorder, Puntuaciones de riesgo transcriptómico; Trastorno por déficit de atención e hiperactividad, Puntuació de risc transcriptòmic; Trastorn per dèficit d'atenció i hiperactivitat, Attention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood. Based on TWAS results, we selected subsets of genes and constructed transcriptomic risk scores (TRSs) for the disorder in peripheral blood mononuclear cells of individuals with ADHD and controls. We found evidence of association between ADHD and TRSs constructed using expression profiles from multiple brain areas, with individuals with ADHD carrying a higher burden of TRSs than controls. TRSs were uncorrelated with the polygenic risk score (PRS) for ADHD and, in combination with PRS, improved significantly the proportion of variance explained over the PRS-only model. These results support the complementary predictive potential of genetic and transcriptomic profiles in blood and underscore the potential utility of gene expression for risk prediction and deeper insight in molecular mechanisms underlying ADHD., This work was supported by the Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, 2017SGR-1461, 2021SGR-00840), the Instituto de Salud Carlos III and co-funded by the European Union Found: Fondo Social Europeo Plus (FSE+) (P19/01224, PI20/00041, PI22/00464 and FI18/00285 to LVR, CP22/00128 to MSA and CP22/00026 to SA), the Ministry of Science, Innovation and Universities (IJC2018-035346-I to MSA and RYC2021-031324-I to JCD), the Network Center for Biomedical Research (CIBER) to JCD, the European Regional Development Fund (ERDF), the European Union H2020 Programme (H2020/2014-2020) under grant agreements no. 728018 (Eat2beNICE), no. 848228 (DISCOvERIE) and no. 2020604 (TIMESPAN), the ECNP Network ‘ADHD across the Lifespan’ and the “la Marató de TV3” (202228-30 and 202228-31). ADB was supported by grants from the Lundbeck Foundation (R102-A9118, R155-2014-1724, and R248-2017-2003) and NIH/NIMH (1R01MH124851-01). DD was supported by the Novo Nordisk Foundation (NNF20OC0065561) and the Lundbeck Foundation (R344-2020-1060).